Cesare Calandri
University of Rome Tor Vergata · 29 works · 1,810 citations · h-index 16
Top works
- Akt Phosphorylation and Gefitinib Efficacy in Patients With Advanced Non-Small-Cell Lung Cancer
- Gefitinib in Pretreated Non–Small-Cell Lung Cancer (NSCLC): Analysis of Efficacy and Correlation With HER2 and Epidermal Growth Factor Receptor Expression in Locally Advanced or Metastatic NSCLC
- Gemcitabine as Second-Line Treatment for Advanced Non–Small-Cell Lung Cancer: A Phase II Trial
- EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients
- Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC)
- A three-week schedule of gemcitabine–cisplatin in advanced non-small-cell lung cancer with two different cisplatin dose levels: A phase II randomized trial
- Antiphospholipid Antibodies Accelerate Plasma Coagulation by Inhibiting Annexin-V Binding to Phospholipids: A “Lupus Procoagulant” Phenomenon
- The expression of the placental anticoagulant protein, annexin V, by villous trophoblasts: Immunolocalization and in vitro regulation
- ZD 1839 in patients with brain metastases from non-small-cell lung cancer (NSCLC): report of four cases
- Gemcitabine-associated CD8+ CD30+ pseudolymphoma.
- Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC)
- Gemcitabine in advanced pancreatic cancer: A phase II trial
- Renal Failure Due to Leukaemic Infiltration in Chronic Lymphocytic Leukaemia
- Gemzar platinum combinations: phase III trials in non-small cell lung cancer
- Medical treatment of brain metastases from solid tumours.
- 74 Salvage therapy with gemcitabine (GEM) in pretreated, advanced non-small cell lung cancer (NSCLC)
- Gemcitabine as second-line treatment for relapsing or refractory advanced non-small cell lung cancer: a phase II trial.
- Gemcitabine in Advanced Pancreatic Cancer
- Challenging Problems in Malignancy
- Estramustine potentiates taxane in prostate and refractory breast cancers.